Enliven Therapeutics (NASDAQ:ELVN) Trading Up 6.4% After Analyst Upgrade

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s stock price rose 6.4% during mid-day trading on Tuesday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The company traded as high as $40.94 and last traded at $42.1210. Approximately 20,392 shares traded hands during trading, a decline of 98% from the average daily volume of 1,169,657 shares. The stock had previously closed at $39.59.

ELVN has been the subject of several other reports. HC Wainwright boosted their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. The Goldman Sachs Group lifted their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Finally, Mizuho increased their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $53.17.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 10,000 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. This trade represents a 16.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard A. Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the transaction, the director directly owned 22,647 shares in the company, valued at $592,898.46. This trade represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV acquired a new stake in Enliven Therapeutics in the first quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after acquiring an additional 594 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the last quarter. Quantbot Technologies LP lifted its holdings in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares during the last quarter. Finally, AlphaQuest LLC acquired a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at approximately $96,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Stock Performance

The firm’s fifty day moving average is $37.48 and its 200-day moving average is $27.59. The company has a market capitalization of $2.62 billion, a P/E ratio of -25.76 and a beta of 0.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.7 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.